L’avenir de l’oncologie passe-t-il par la médecine nucléaire ?

L’avenir de l’oncologie passe-t-il par la médecine nucléaire ?,10.1016/j.mednuc.2008.02.002,Medecine Nucleaire-imagerie Fonctionnelle Et Metabolique,J

L’avenir de l’oncologie passe-t-il par la médecine nucléaire ?   (Citations: 1)
BibTex | RIS | RefWorks Download
During the last decennials, nuclear medicine demonstrated a lot of significant progresses, so that “nuclear oncology” could be considered now as a well recognized entity. These progresses have been made on one hand in the diagnostic field, and on the other hand for therapeutic applications of radiopharmaceuticals able to target tumour cells, the number and performances of which being continuously growing. For diagnosis, beyond its capability to visualize tumour lesions otherwise difficult to demonstrate, it could be said that nuclear medicine is useful for the tumour characterization, allowing imaging of prognosis factors and criteria of treatment's choice, and evaluation of treatments efficiency as well. In the therapeutic field, while thyroid carcinomas treatment using iodine 131 is still of interest and benefits of recent improvements, internal targeted radiotherapy is clearly becoming clinically useful, as it has been proved that it could improve patients’ survival in combination with other treatments. That is true for radio-immunotherapy of follicular lymphoma and bone metastasis treatment, and probably in the very near future for several solid tumours. This paper reviews the most significant aspects of these recent progresses, in order to convince that nuclear oncology has become a full part of oncology.
Journal: Medecine Nucleaire-imagerie Fonctionnelle Et Metabolique - MED NUCL , vol. 32, no. 4, pp. 249-253, 2008
Cumulative Annual
View Publication
The following links allow you to view full publications. These links are maintained by other sources not affiliated with Microsoft Academic Search.
Sort by: